Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 4/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676746 | 1.00 | DRD2 (0.47) | DRD2MAPTPOLBNLRP3EP300 | |
| Methane SCHEMBL1677187 | 0.99 | POLB (0.47) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1480798 | 0.97 | DRD2 (0.49) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1480801 | 0.97 | DRD2 (0.49) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1480789 | 0.96 | DRD2 (0.44) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1480792 | 0.96 | DRD2 (0.44) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1481341 | 0.93 | DRD2 (0.46) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1481338 | 0.93 | DRD2 (0.46) | DRD2MAPTPOLBNLRP3EP300 | |
| SCHEMBL1676516 | 0.92 | DRD2 (0.48) | DRD2MAPTPOLBNLRP3TBXA2R | |
| SCHEMBL1676512 | 0.92 | DRD2 (0.48) | DRD2MAPTPOLBNLRP3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | DRD2 4873/4885MAPT 3251/4885POLB 4497/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | DRD2 4873/4885MAPT 3251/4885POLB 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.